# A Study to Assess the Pharmacokinetics (Uptake of Drugs by the Body), Safety and Tolerability of AZD4831 in Participants With Severe Renal Impairment and Healthy Volunteers

> **NCT04949438** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 20 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** AZD4831

## Key facts

- **NCT ID:** NCT04949438
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-21
- **Primary completion:** 2022-03-04
- **Final completion:** 2022-03-04
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2022-04-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04949438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04949438, "A Study to Assess the Pharmacokinetics (Uptake of Drugs by the Body), Safety and Tolerability of AZD4831 in Participants With Severe Renal Impairment and Healthy Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04949438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*